“A new paradigm for treating metabolic diseases.”
ABOUT US
Eternygen is a Berlin based start up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen’s development and core competences of its founders are research and development of new drugs for aging and dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Eternygen’s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of citrate metabolism involved in the pathogenesis of chronic kidney diseases, fatty liver, diabetes and obesity.
The company’s emphasis is the development of a safe and effective drug for treatment of these widespread diseases via targeted adjustment of underlying metabolic failure.
RESEARCH & DEVELOPMENT
LITERATUR & PAPER
Dipender et al. 2023 – Preprint: MedRxiv
The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development
Stefan et al. 2023 – Cell Metabolism
The role of hepatokines in NAFLD
Zahn et al. 2022 – Metabolites
A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity
Pesta and Jordan 2022 – Metabolites
INDY as a Therapeutic Target for Cardio-Metabolic Disease
OUR TEAM
Partners & Collaborators
